175 related articles for article (PubMed ID: 36672171)
1. The Alternative TrkAIII Splice Variant, a Targetable Oncogenic Participant in Human Cutaneous Malignant Melanoma.
Cappabianca L; Zelli V; Pellegrini C; Sebastiano M; Maccarone R; Clementi M; Chiominto A; Ruggeri P; Cardelli L; Ruggieri M; Sbaffone M; Fargnoli MC; Guadagni S; Farina AR; Mackay AR
Cells; 2023 Jan; 12(2):. PubMed ID: 36672171
[TBL] [Abstract][Full Text] [Related]
2. The oncogenic neurotrophin receptor tropomyosin-related kinase variant, TrkAIII.
Farina AR; Cappabianca L; Ruggeri P; Gneo L; Pellegrini C; Fargnoli MC; Mackay AR
J Exp Clin Cancer Res; 2018 Jun; 37(1):119. PubMed ID: 29914559
[TBL] [Abstract][Full Text] [Related]
3. A pilot study of alternative TrkAIII splicing in Merkel cell carcinoma: a potential oncogenic mechanism and novel therapeutic target.
Cappabianca L; Guadagni S; Maccarone R; Sebastiano M; Chiominto A; Farina AR; Mackay AR
J Exp Clin Cancer Res; 2019 Oct; 38(1):424. PubMed ID: 31640749
[TBL] [Abstract][Full Text] [Related]
4. Multidisciplinary Treatment, Including Locoregional Chemotherapy, for Merkel-Polyomavirus-Positive Merkel Cell Carcinomas: Perspectives for Patients Exhibiting Oncogenic Alternative Δ exon 6-7 TrkAIII Splicing of Neurotrophin Receptor Tropomyosin-Related Kinase A.
Guadagni S; Farina AR; Cappabianca LA; Sebastiano M; Maccarone R; Zelli V; Clementi M; Chiominto A; Bruera G; Ricevuto E; Fiorentini G; Sarti D; Mackay AR
Int J Mol Sci; 2020 Nov; 21(21):. PubMed ID: 33153070
[TBL] [Abstract][Full Text] [Related]
5. Doxorubicin-Induced TrkAIII Activation: A Selection Mechanism for Resistant Dormant Neuroblastoma Cells.
Cappabianca L; Sebastiano M; Ruggieri M; Sbaffone M; Zelli V; Farina AR; Mackay AR
Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142807
[TBL] [Abstract][Full Text] [Related]
6. The neuroblastoma tumour-suppressor TrkAI and its oncogenic alternative TrkAIII splice variant exhibit geldanamycin-sensitive interactions with Hsp90 in human neuroblastoma cells.
Farina AR; Tacconelli A; Cappabianca L; Cea G; Chioda A; Romanelli A; Pensato S; Pedone C; Gulino A; Mackay AR
Oncogene; 2009 Nov; 28(46):4075-94. PubMed ID: 19734938
[TBL] [Abstract][Full Text] [Related]
7. Retrograde TrkAIII transport from ERGIC to ER: a re-localisation mechanism for oncogenic activity.
Farina AR; Cappabianca L; Ruggeri P; Gneo L; Maccarone R; Mackay AR
Oncotarget; 2015 Nov; 6(34):35636-51. PubMed ID: 26415233
[TBL] [Abstract][Full Text] [Related]
8. A Study of Alternative TrkA Splicing Identifies TrkAIII as a Novel Potentially Targetable Participant in PitNET Progression.
Sbaffone M; Jaffrain-Rea ML; Cappabianca L; Carbonara F; Gianno F; Feola T; Ruggieri M; Zelli V; Maccarone R; Guadagni S; Clementi M; Arcella A; Esposito V; Carozza G; Martelli I; Farina AR; Mackay AR
Biology (Basel); 2024 Mar; 13(3):. PubMed ID: 38534441
[TBL] [Abstract][Full Text] [Related]
9. The alternative TrkAIII splice variant targets the centrosome and promotes genetic instability.
Farina AR; Tacconelli A; Cappabianca L; Cea G; Panella S; Chioda A; Romanelli A; Pedone C; Gulino A; Mackay AR
Mol Cell Biol; 2009 Sep; 29(17):4812-30. PubMed ID: 19564412
[TBL] [Abstract][Full Text] [Related]
10. Alternative TrkAIII splicing: a potential regulated tumor-promoting switch and therapeutic target in neuroblastoma.
Tacconelli A; Farina AR; Cappabianca L; Gulino A; Mackay AR
Future Oncol; 2005 Oct; 1(5):689-98. PubMed ID: 16556046
[TBL] [Abstract][Full Text] [Related]
11. TrkAIII promotes microtubule nucleation and assembly at the centrosome in SH-SY5Y neuroblastoma cells, contributing to an undifferentiated anaplastic phenotype.
Farina AR; Di Ianni N; Cappabianca L; Ruggeri P; Ragone M; Ianni G; Gulino A; Mackay AR
Biomed Res Int; 2013; 2013():740187. PubMed ID: 23841091
[TBL] [Abstract][Full Text] [Related]
12. TrkAIII expression in the thymus.
Tacconelli A; Farina AR; Cappabianca L; Cea G; Panella S; Chioda A; Gallo R; Cinque B; Sferra R; Vetuschi A; Campese AF; Screpanti I; Gulino A; Mackay AR
J Neuroimmunol; 2007 Feb; 183(1-2):151-61. PubMed ID: 17241672
[TBL] [Abstract][Full Text] [Related]
13. The TrkAIII oncoprotein inhibits mitochondrial free radical ROS-induced death of SH-SY5Y neuroblastoma cells by augmenting SOD2 expression and activity at the mitochondria, within the context of a tumour stem cell-like phenotype.
Ruggeri P; Farina AR; Di Ianni N; Cappabianca L; Ragone M; Ianni G; Gulino A; Mackay AR
PLoS One; 2014; 9(4):e94568. PubMed ID: 24736663
[TBL] [Abstract][Full Text] [Related]
14. TrkAIII. A novel hypoxia-regulated alternative TrkA splice variant of potential physiological and pathological importance.
Tacconelli A; Farina AR; Cappabianca L; Gulino A; Mackay AR
Cell Cycle; 2005 Jan; 4(1):8-9. PubMed ID: 15611661
[TBL] [Abstract][Full Text] [Related]
15. TRAIL induces pro-apoptotic crosstalk between the TRAIL-receptor signaling pathway and TrkAIII in SH-SY5Y cells, unveiling a potential therapeutic "Achilles heel" for the TrkAIII oncoprotein in neuroblastoma.
Gneo L; Ruggeri P; Cappabianca L; Farina AR; Di Ianni N; Mackay AR
Oncotarget; 2016 Dec; 7(49):80820-80841. PubMed ID: 27821809
[TBL] [Abstract][Full Text] [Related]
16. TrkA alternative splicing: a regulated tumor-promoting switch in human neuroblastoma.
Tacconelli A; Farina AR; Cappabianca L; Desantis G; Tessitore A; Vetuschi A; Sferra R; Rucci N; Argenti B; Screpanti I; Gulino A; Mackay AR
Cancer Cell; 2004 Oct; 6(4):347-60. PubMed ID: 15488758
[TBL] [Abstract][Full Text] [Related]
17. Novel transcripts reveal a complex structure of the human TRKA gene and imply the presence of multiple protein isoforms.
Luberg K; Park R; Aleksejeva E; Timmusk T
BMC Neurosci; 2015 Nov; 16():78. PubMed ID: 26581861
[TBL] [Abstract][Full Text] [Related]
18. TrkAIII signals endoplasmic reticulum stress to the mitochondria in neuroblastoma cells, resulting in glycolytic metabolic adaptation.
Farina AR; Cappabianca L; Gneo L; Ruggeri P; Mackay AR
Oncotarget; 2018 Feb; 9(9):8368-8390. PubMed ID: 29492201
[TBL] [Abstract][Full Text] [Related]
19. TrkA is amplified in malignant melanoma patients and induces an anti-proliferative response in cell lines.
Pasini L; Re A; Tebaldi T; Ricci G; Boi S; Adami V; Barbareschi M; Quattrone A
BMC Cancer; 2015 Oct; 15():777. PubMed ID: 26496938
[TBL] [Abstract][Full Text] [Related]
20. Oncogenic BRAF, endoplasmic reticulum stress, and autophagy: Crosstalk and therapeutic targets in cutaneous melanoma.
Rather RA; Bhagat M; Singh SK
Mutat Res Rev Mutat Res; 2020; 785():108321. PubMed ID: 32800272
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
